- Home
- KURA vs ELE Comparison
KURA vs ELE Comparison
Compare KURA & ELE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KURA | ELE |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2015 | 2025 |
Fundamental Metrics
Financial Performance| Metric | KURA | ELE |
|---|---|---|
| Price | $13.03 | $21.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | $25.56 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 2.2M | 264.6K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 0.18% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,482,000.00 | N/A |
| Revenue This Year | $28.28 | $109.25 |
| Revenue Next Year | $106.37 | $16.14 |
| P/E Ratio | ★ N/A | $255.64 |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $7.36 | $14.01 |
| 52 Week High | $13.90 | $26.96 |
Technical Indicators
Market Signals| Indicator | KURA | ELE |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 59.15 |
| Support Level | $7.96 | $20.87 |
| Resistance Level | $13.90 | $22.45 |
| Average True Range (ATR) | 0.68 | 0.81 |
| MACD | 0.09 | -0.23 |
| Stochastic Oscillator | 73.57 | 42.36 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About ELE Elemental Royalty Corporation
Elemental Royalty Corp is engaged in exploration discovery, royalty generation, royalty acquisition, and strategic investments. It is the result of the strategic merger of Elemental Altus Royalties and EMX Royalty Corporation together creating a mid-tier gold-focused royalty company with the scale, diversification, and cash flow. Geographically, the company generates revenue from North America, South America, Europe, Australia and Africa.